Therapies & Progress

Esperion Therapeutics is focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.

Esperion’s portfolio includes one product candidate in Phase 2 clinical development, ETC-1002, and two early-stage product candidates, ESP41091¬†and ApoA-1 Mimetics.

Esperion owns the exclusive worldwide rights to all three compounds.

Esperion Portfolio

Esperion Portfolio 100614